glp-1 obesity drug news today october 2025 27 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response GLP-1 Weight-Loss Drug Retatrutide, the next generation of

Research progress of sarcopenia: Diagnostic advancements, molecular mechanisms, and therapeutic strategies

34,35 However, the controversy surrounding the possible benefits of GIPR agonism stems from two main observations: its impaired insulinotropic effects, 36,37 and the prevention of weight gain by suppression of endogenous GIP-induced adipogenesis, 38,39 However, these seemingly discouraging observations have been questioned by the finding of the central anorexic effects of GIP, 4042 and benefits of the GLP-1R/GIPR dual agonist LY3298176 (tirzepatide) in diabetic and overweight individuals

Mooney, F

Role of oxidative stress in development of cardiovascular complications in diabetes mellitus